FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4210967674> ?p ?o ?g. }

• W4210967674 abstract "Buerger's disease (thromboangiitis obliterans) is a non-atherosclerotic, segmental inflammatory pathology that most commonly affects the small and medium sized arteries, veins, and nerves in the upper and lower extremities. The aetiology is unknown, but involves hereditary susceptibility, tobacco exposure, immune and coagulation responses. In many cases, there is no possibility of revascularisation to improve the condition. Pharmacological treatment is an option for patients with severe complications, such as ischaemic ulcers or rest pain.This is an update of the review first published in 2016.To assess the effectiveness of any pharmacological agent (intravenous or oral) compared with placebo or any other pharmacological agent in patients with Buerger's disease.The Cochrane Vascular Information Specialist searched the Cochrane Vascular Specialised Register, Cochrane Central Register of Controlled Trials, MEDLINE, Embase, CINAHL, AMED, the World Health Organization International Clinical Trials Registry Platform and ClinicalTrials.gov trials register to 15 October 2019. The review authors searched LILACS, ISRCTN, Australian New Zealand Clinical Trials Registry, EU Clinical Trials Register, clincialtrials.gov and the OpenGrey Database to 5 January 2020.We included randomised controlled trials (RCTs) involving pharmacological agents used in the treatment of Buerger's disease.Two review authors, independently assessed the studies, extracted data and performed data analysis.No new studies were identified for this update. Five randomised controlled trials (total 602 participants) compared prostacyclin analogue with placebo, aspirin, or a prostaglandin analogue, and folic acid with placebo. No studies assessed other pharmacological agents such as cilostazol, clopidogrel and pentoxifylline or compared oral versus intravenous prostanoid. Compared with aspirin, intravenous prostacyclin analogue iloprost improved ulcer healing (risk ratio (RR) 2.65; 95% confidence interval (CI) 1.15 to 6.11; 98 participants; 1 study; moderate-certainty evidence), and helped to eradicate rest pain after 28 days (RR 2.28; 95% CI 1.48 to 3.52; 133 participants; 1 study; moderate-certainty evidence), although amputation rates were similar six months after treatment (RR 0.32; 95% CI 0.09 to 1.15; 95 participants; 1 study; moderate-certainty evidence). When comparing prostacyclin (iloprost and clinprost) with prostaglandin (alprostadil) analogues, ulcer healing was similar (RR 1.13; 95% CI 0.76 to 1.69; 89 participants; 2 studies; I² = 0%; very low-certainty evidence), as was the eradication of rest pain after 28 days (RR 1.57; 95% CI 0.72 to 3.44; 38 participants; 1 study; low-certainty evidence), while amputation rates were not measured. Compared with placebo, the effects of oral prostacyclin analogue iloprost were similar for: healing ischaemic ulcers (iloprost 200 mcg: RR 1.11; 95% CI 0.54 to 2.29; 133 participants; 1 study; moderate-certainty evidence, and iloprost 400 mcg: RR 0.90; 95% CI 0.42 to 1.93; 135 participants; 1 study; moderate-certainty evidence), eradication of rest pain after eight weeks (iloprost 200 mcg: RR 1.14; 95% CI 0.79 to 1.63; 207 participants; 1 study; moderate-certainty evidence, and iloprost 400 mcg: RR 1.11; 95% CI 0.77 to 1.59; 201 participants; 1 study; moderate-certainty evidence), and amputation rates after six months (iloprost 200 mcg: RR 0.54; 95% CI 0.19 to 1.56; 209 participants; 1 study, and iloprost 400 mcg: RR 0.42; 95% CI 0.13 to 1.31; 213 participants; 1 study). When comparing folic acid with placebo in patients with Buerger's disease and hyperhomocysteinaemia, pain scores were similar, there were no new cases of amputation in either group, and ulcer healing was not assessed (very low-certainty evidence). Treatment side effects such as headaches, flushing or nausea were not associated with treatment interruptions or more serious consequences. Outcomes such as amputation-free survival, walking distance or pain-free walking distance, and ankle brachial index were not assessed by any study. Overall, the certainty of the evidence was very low to moderate, with few studies, small numbers of participants, variation in severity of disease of participants between studies and missing information (for example regarding baseline tobacco exposure).Moderate-certainty evidence suggests that intravenous iloprost (prostacyclin analogue) is more effective than aspirin for eradicating rest pain and healing ischaemic ulcers in Buerger's disease, but oral iloprost is not more effective than placebo. Very low and low-certainty evidence suggests there is no clear difference between prostacyclin (iloprost and clinprost) and the prostaglandin analogue alprostadil for healing ulcers and relieving pain respectively in severe Buerger's disease. Very low-certainty evidence suggests there is no clear difference in pain scores and amputation rates between folic acid and placebo, in people with Buerger's disease and hyperhomocysteinaemia. Further well designed RCTs assessing the effectiveness of pharmacological agents (intravenous or oral) in people with Buerger's disease are needed." @default.
• W4210967674 created "2022-02-13" @default.
• W4210967674 creator A5042072626 @default.
• W4210967674 creator A5049692202 @default.
• W4210967674 creator A5078856561 @default.
• W4210967674 creator A5089315797 @default.
• W4210967674 date "2020-05-04" @default.
• W4210967674 modified "2023-10-16" @default.
• W4210967674 title "Pharmacological treatment for Buerger's disease" @default.
• W4210967674 cites W1247968195 @default.
• W4210967674 cites W1506693614 @default.
• W4210967674 cites W1695362599 @default.
• W4210967674 cites W173438471 @default.
• W4210967674 cites W1948704512 @default.
• W4210967674 cites W1975658497 @default.
• W4210967674 cites W1990718969 @default.
• W4210967674 cites W1997718908 @default.
• W4210967674 cites W2000884814 @default.
• W4210967674 cites W2002180181 @default.
• W4210967674 cites W2002893478 @default.
• W4210967674 cites W2005646883 @default.
• W4210967674 cites W2041521820 @default.
• W4210967674 cites W2042117861 @default.
• W4210967674 cites W2050100210 @default.
• W4210967674 cites W2057133437 @default.
• W4210967674 cites W2059404773 @default.
• W4210967674 cites W2060989736 @default.
• W4210967674 cites W2069019463 @default.
• W4210967674 cites W2073574950 @default.
• W4210967674 cites W2084679456 @default.
• W4210967674 cites W2116006231 @default.
• W4210967674 cites W2130360326 @default.
• W4210967674 cites W2148311951 @default.
• W4210967674 cites W2163154920 @default.
• W4210967674 cites W2169171235 @default.
• W4210967674 cites W2290715207 @default.
• W4210967674 cites W2416162974 @default.
• W4210967674 cites W2416542070 @default.
• W4210967674 cites W2470223113 @default.
• W4210967674 cites W3109997177 @default.
• W4210967674 cites W3158144670 @default.
• W4210967674 cites W4212996341 @default.
• W4210967674 cites W4240123733 @default.
• W4210967674 cites W4253457320 @default.
• W4210967674 cites W67911001 @default.
• W4210967674 cites W2003556449 @default.
• W4210967674 cites W2428505212 @default.
• W4210967674 doi "https://doi.org/10.1002/14651858.cd011033.pub4" @default.
• W4210967674 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32364620" @default.
• W4210967674 hasPublicationYear "2020" @default.
• W4210967674 type Work @default.
• W4210967674 citedByCount "8" @default.
• W4210967674 countsByYear W42109676742021 @default.
• W4210967674 countsByYear W42109676742022 @default.
• W4210967674 countsByYear W42109676742023 @default.
• W4210967674 crossrefType "journal-article" @default.
• W4210967674 hasAuthorship W4210967674A5042072626 @default.
• W4210967674 hasAuthorship W4210967674A5049692202 @default.
• W4210967674 hasAuthorship W4210967674A5078856561 @default.
• W4210967674 hasAuthorship W4210967674A5089315797 @default.
• W4210967674 hasBestOaLocation W42109676742 @default.
• W4210967674 hasConcept C126322002 @default.
• W4210967674 hasConcept C141071460 @default.
• W4210967674 hasConcept C142724271 @default.
• W4210967674 hasConcept C204787440 @default.
• W4210967674 hasConcept C27081682 @default.
• W4210967674 hasConcept C2777628954 @default.
• W4210967674 hasConcept C2779134260 @default.
• W4210967674 hasConcept C2781265703 @default.
• W4210967674 hasConcept C535046627 @default.
• W4210967674 hasConcept C71924100 @default.
• W4210967674 hasConceptScore W4210967674C126322002 @default.
• W4210967674 hasConceptScore W4210967674C141071460 @default.
• W4210967674 hasConceptScore W4210967674C142724271 @default.
• W4210967674 hasConceptScore W4210967674C204787440 @default.
• W4210967674 hasConceptScore W4210967674C27081682 @default.
• W4210967674 hasConceptScore W4210967674C2777628954 @default.
• W4210967674 hasConceptScore W4210967674C2779134260 @default.
• W4210967674 hasConceptScore W4210967674C2781265703 @default.
• W4210967674 hasConceptScore W4210967674C535046627 @default.
• W4210967674 hasConceptScore W4210967674C71924100 @default.
• W4210967674 hasLocation W42109676741 @default.
• W4210967674 hasLocation W42109676742 @default.
• W4210967674 hasLocation W42109676743 @default.
• W4210967674 hasLocation W42109676744 @default.
• W4210967674 hasOpenAccess W4210967674 @default.
• W4210967674 hasPrimaryLocation W42109676741 @default.
• W4210967674 hasRelatedWork W2002120878 @default.
• W4210967674 hasRelatedWork W2047409473 @default.
• W4210967674 hasRelatedWork W2047967234 @default.
• W4210967674 hasRelatedWork W2064286441 @default.
• W4210967674 hasRelatedWork W2101077504 @default.
• W4210967674 hasRelatedWork W2366434335 @default.
• W4210967674 hasRelatedWork W2439875401 @default.
• W4210967674 hasRelatedWork W2950169628 @default.
• W4210967674 hasRelatedWork W3204761618 @default.
• W4210967674 hasRelatedWork W4214780584 @default.
• W4210967674 isParatext "false" @default.
• W4210967674 isRetracted "false" @default.
• W4210967674 workType "article" @default.